---
title: Real-world analysis of teclistamab in 123 RRMM patients from Germany
date: '2024-01-20'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38245601/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240121170623&v=2.18.0
source: heidelberg[Affiliation]
description: Teclistamab, a B-cell maturation antigen (BCMA) × CD3 directed bispecific
  antibody, has shown high response rates and durable remissions in the MAJESTEC-1
  trial in patients with relapsed and refractory multiple myeloma (RRMM). We retrospectively
  assessed efficacy and tolerability in 123 patients treated at 18 different German
  centers to determine whether outcome is comparable in the real-world setting. Most
  patients had triple-class (93%) or penta-drug (60%) refractory disease, 37% of ...
disable_comments: true
---
Teclistamab, a B-cell maturation antigen (BCMA) × CD3 directed bispecific antibody, has shown high response rates and durable remissions in the MAJESTEC-1 trial in patients with relapsed and refractory multiple myeloma (RRMM). We retrospectively assessed efficacy and tolerability in 123 patients treated at 18 different German centers to determine whether outcome is comparable in the real-world setting. Most patients had triple-class (93%) or penta-drug (60%) refractory disease, 37% of ...